BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6846253)

  • 1. Phase I study of cyclophosphamide (NSC 26271) by 72-hour continuous intravenous infusion.
    Bedikian AY; Bodey GP
    Am J Clin Oncol; 1983 Jun; 6(3):365-8. PubMed ID: 6846253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.
    Tchekmedyian NS; Egorin MJ; Cohen BE; Kaplan RS; Poplin E; Aisner J
    Cancer Chemother Pharmacol; 1986; 18(1):33-8. PubMed ID: 3757157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors.
    Davila E; Klein L; Vogel CL; Johnson R; Ostroy F; Browning S; Gorowski E; Furner RL; Presant CA
    J Clin Oncol; 1985 Jan; 3(1):121-7. PubMed ID: 3965629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
    J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
    Weiss GR; Kuhn JG; Rizzo J; Smith LS; Rodriguez GI; Eckardt JR; Burris HA; Fields S; VanDenBerg K; von Hoff DD
    Cancer Chemother Pharmacol; 1995; 35(5):397-402. PubMed ID: 7850921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
    Tolcher AW; Cowan KH; Noone MH; Denicoff AM; Kohler DR; Goldspiel BR; Barnes CS; McCabe M; Gossard MR; Zujewski J; O'Shaughnessy JA
    J Clin Oncol; 1996 Jan; 14(1):95-102. PubMed ID: 8558227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion.
    Kuhn JG; Von Hoff DD; Hersh M; Melink T; Clark GM; Weiss GR; Coltman CA
    Eur J Cancer Clin Oncol; 1989 May; 25(5):797-803. PubMed ID: 2737217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
    Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
    J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer.
    Hietanen P; Teerenhovi L; Joensuu H
    Oncology; 1999; 56(2):103-9. PubMed ID: 9949294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion.
    Leyvraz S; Ohnuma T; Lassus M; Holland JF
    J Clin Oncol; 1985 Oct; 3(10):1385-92. PubMed ID: 3900302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
    Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
    Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of spirogermanium given daily.
    Legha SS; Ajani JA; Bodey GP
    J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer.
    Kouroussis C; Kalbakis K; Androulakis N; Agelaki S; Vamvakas L; Malas K; Souglakos J; Vardakis N; Georgoulias V
    Anticancer Res; 2004; 24(6):4217-21. PubMed ID: 15736475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of aziridinylbenzoquinone (NSC 182986).
    Bedikian AY; Bodey GP; Burgess MA; Freireich EJ
    Cancer Clin Trials; 1981; 4(4):459-63. PubMed ID: 7318128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.